THE WHAT? Kimberly-Clark has reported a 30 p.c improve in Rogaine gross sales this 12 months, with rising adoption of GLP-1 weight-loss drugs doubtlessly contributing to elevated demand for hair loss remedies.
THE DETAILS Kimberly-Clark CEO Mike Hsu highlighted the expansion throughout an analyst name, suggesting that rising use of GLP-1 drugs might be supporting demand for Rogaine, which joined the corporate’s portfolio by way of its acquisition of Kenvue. Speedy weight reduction has been related to short-term hair shedding, creating further demand for focused hair care remedies, though a direct hyperlink between GLP-1 drugs and Rogaine’s gross sales development has not been established. Rogaine holds roughly 9 p.c of the worldwide hair loss prevention market,valued at round valued at round US$10 billion in 2025 and projected to succeed in US$ 23 billion by 2035,, in accordance with Future Market Insights.
THE WHY? Rogaine’s efficiency highlights rising industrial demand for focused hair loss remedies as altering shopper well being and life-style traits affect the worldwide hair care market. The gross sales improve demonstrates the potential for established therapy manufacturers to profit from rising shopper wants with out counting on new product launches.
Supply: Bloomberg
